Genes of killer cell immunoglobulin-like receptors and their HLA ligands after allogeneic hematopoietic stem cell transplantation in myeloid leukemia patients


Cite item

Full Text

Abstract

Aim. To study the impact of the genes of donor killer cell immunoglobulin-like receptors (KIR) and HLA—KIR ligands on overall (OS) and event-free survival (EFS) rates in patients with myeloid leukemia after transplantation with allogeneic hematopoietic stem cells (allo-HSCT) from HLA-identical related and HLA-compatible unrelated donors. Subjects and methods. The investigation enrolled 29 patients who had undergone allo-HSCT from KIR-genotyped donors at the Department of Bone Marrow Transplantation, Hematology Research Centerб in 2010-2013. OS and EFS rates after allo-HSCT were calculated using the Kaplan-Meier method. Results. The main predictor of recurrence and survival in patients after allo-HSCT was a recurrence-risk group the patient belonged to before transplantation. The standard-risk group patients whose donors had telomeric gene-content motifs of KIR-B haplotypes had higher EFS rates than those whose donors lacked these genes. The standard-risk patients homozygous for HLA-1 alleles (i.e. without HLA-C2 ligand) tended to have higher EFS rates, so did the patients without HLA-Bw4 ligand. Conclusion. The donors having telomeric gene-content motifs of KIR-B haplotypes are more preferred for allo-HSCT for patients with myeloid leukemia as the presence of donor telomeric KIR-B genes increases EFS rates in standard-risk patients.

References

  1. Савченко В.Г., Любимова Л.С., Паровичникова Е.Н., Менделеева Л.И., Момотюк К.С., Демидова И.А., Грибанова Е.О., Гальцева И.В., Покровская О.С., Кузьмина Л.А., Желнова Е.И., Клясова Г.А., Гласко Е.Н., Капланская И.Б., Порешина Л.П., Кутьина Р.М., Шпакова А.П., Штарева Е.М., Варламова С.В., Калинин Н.Н. Трансплантации аллогенных и аутологичных гемопоэтических стволовых клеток при острых лейкозах (Итоги 20-летнего опыта). Терапевтический архив. 2007;7:30-35.
  2. Кузьмина Л.А., Любимова Л.С., Менделеева Л.П., Желнова Е.И., Петинати Н.А., Богданов Р.Ф., Васильева В.А., Гапонова Т.В., Капланская И.Б., Костина И.Э., Шавлохов В.С., Грибанова О.Е., Обухова Т.Н., Паровичникова Е.Н., Савченко В.Г. Экстрамедуллярные рецидивы после трансплантации аллогенных гемопоэтических клеток и трансфузий лимфоцитов донора. Клиническая онкогематология. 2011;4(3): 191-195.
  3. Любимова Л.С., Кузьмина Л.А., Урнова Е.С., Желнова Е.И., Анухина М.В., Менделеева Л.П., Гапонова Т.В., Гальцева И.В., Покровская О.С., Кутьина Р.М., Васильева М.Н., Шпакова А.П., Хамаганова Е. Г., Булычева Т. И., Домрачева Е. В., Варламова С.В., Калинин Н.Н., Гласко Е.Н., Капланская И.Б., Паровичникова Е.Н, Савченко В.Г. HLA-идентичная трансплантация костного мозга в первой хронической фазе хронического миелолейкоза в ранние сроки заболевания или длительная терапия ингибиторами тирозинкиназ? Гематология и трансфузиология. 2012;57(3):6-10.
  4. Russel JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu RevImmunol. 2002;20(4):323-370.
  5. Lundquist A, McCoy JP, Samsel L, Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood. 2007;109(8):3603-3606.
  6. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics. 2002;54(4):221-229.
  7. Single RM, Martin MP, Meyer D, Gao X, Carrington M. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics. 2008;60(12):711-725.
  8. Хамаганова Е.Г., Сучкова М.В., Элижбаева М.А., Судариков А.Б. Гены KIR-иммуноглобулиноподобных рецепторов естественных киллерных клеток в двух популяциях РФ. Иммунология. 2011;6:284-291.
  9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562): 2097-2100.
  10. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825-3827.
  11. Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G, Wolf D, Gastl G, Nachbaur D. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant. 2010;16(2):273-280.
  12. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-4884.
  13. Clausen J, Wolf D, Petzer AL, Schumacher P, Kircher B, Gastl G, Nachbaur D. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol. 2007;148(3):520-528.
  14. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O’Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood. 2009;113(16):3875-3884. doi: 10.1182/blood-2008-09-177055.
  15. Miller JS, Blazar BR. Control of acute myeloid leukemia relapse—dance between KIRs and HLA. N Engl J Med. 2012;367(9): 866-868. doi: 10.1056/nejme1205900.
  16. Verheyden S, Schots R, Duquet W, Demanet CA. Defined donor natural killer cell receptor genotype protects against leukemia relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19(8):1446-1451.
  17. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726-732.
  18. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419. doi: 10.1182/blood-2010-05-283051.
  19. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, Barrett AJ. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(9):1257-1264. doi: 10.1016/j.bbmt.2010.03.004.
  20. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805-816. doi: 10.1056/nejmoa1200503.
  21. Cooley S, Weisdorf DJ, , Lisbeth A, Klein JP, Wang T, Marsh SG, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia. J Immunol. 2014;192(10):4592-4600. doi: 10.4049/jimmunol.1302517.
  22. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. HumImmunol. 2007;68(5):309-323.
  23. Wu GQ, Zhao YM, Lai XY, Luo Y, Tan YM, Shi JM, Li L, Zheng WY, Zhang J, Hu XR, Jin AY, He JS, Xie WZ, Ye XJ, Cai Z, Lin MF, Huang H. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Bone Marrow Transplant. 2010;45(10):1514-1521.
  24. Giebel S, Locatelli F, Wojnar J, Velardi A, Mina T, Giorgiani G, Krawczyk-Kulis M, Markiewicz M, Wylezol I, Holowiecki J. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leukocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol. 2005;131(4):483-486.
  25. Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW, Schwan MA, Grosse-Wilde H, Wernet P, Uhrberg M. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol. 2007;178(6):3918-3923.
  26. Fischer JC, Kobbe G, Enczmann J, Haas R, Uhrberg M. The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics. 2012;64(12):879-885.
  27. Fürst D, Müller С-H, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood. 2013;122(17): 3220-3229.
  28. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115(6): 1166-1174.
  29. Hilton HG, Vago L, Older Aguilar AM, Moesta AK, Graef T, Abi-Rached L, Norman PJ, Guethlein LA, Fleischhauer K, Parham P. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J Immunol. 2012;189(3):1418-1430. doi: 10.4049/jimmunol.1100431.
  30. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11): 5058-5061.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies